INCA-33890

N/A

Report date: 2026/03/11 20:02:12

Base Information

Drug NameINCA-33890

Drug Alias NameINCA33890INCA-33890

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody

Mechanisms of ActionAnti-PD-1Anti-Transforming growth factor beta receptor 2

TargetsProgrammed cell death protein 1Transforming growth factor beta receptor 2

Therapy Area/IndicationsSolid tumoursOvarian NeoplasmsColorectal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgiumCanadaUnited States +[21]

CombinationsNo

Global Highest StatusPhase 3 Clinical

Highest Status in ChinaN/A

Originator CompaniesIncyte Corp

China Registration ClassN/A

Develop Information

Active CompaniesIncyte Corp

Inactive CompaniesN/A

Active IndicationsSolid tumoursOvarian NeoplasmsColorectal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A